Meeting
2022 ASCO Annual Meeting
Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress).
Authors
Nehal J. Lakhani
START Midwest, Grand Rapids, MI
Nehal J. Lakhani , Claire Frances Friedman , Cesar Augusto Perez , Alison Wehr , Suzanne M. McGoldrick , Patricia LoRusso
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT05229900
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3159)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3159
Abstract #
TPS3159
Poster Bd #
147a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.
First Author: Hans Gelderblom
Poster
2016 ASCO Annual Meeting
A Phase 1 study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI4276 in patients with select HER2-expressing advanced solid tumors.
First Author: Erika Paige Hamilton
Poster
2013 ASCO Annual Meeting
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors.
First Author: Michael Ong
Poster
2024 ASCO Annual Meeting
A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
First Author: Alexander I. Spira